Cytosorbents Corporation (CTSO)
NASDAQ: CTSO · Real-Time Price · USD
0.916
-0.044 (-4.54%)
Nov 20, 2024, 4:00 PM EST - Market closed
Cytosorbents Revenue
Cytosorbents had revenue of $9.39M in the quarter ending September 30, 2024, with 6.58% growth. This brings the company's revenue in the last twelve months to $37.74M, up 1.80% year-over-year. In the year 2023, Cytosorbents had annual revenue of $36.35M with 4.79% growth.
Revenue (ttm)
$37.74M
Revenue Growth
+1.80%
P/S Ratio
1.27
Revenue / Employee
$202,901
Employees
186
Market Cap
50.08M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 36.35M | 1.66M | 4.79% |
| Dec 31, 2022 | 34.69M | -8.48M | -19.64% |
| Dec 31, 2021 | 43.17M | 2.16M | 5.27% |
| Dec 31, 2020 | 41.00M | 16.06M | 64.35% |
| Dec 31, 2019 | 24.95M | 2.45M | 10.87% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| 111, Inc. | 2.03B |
| OptiNose | 75.67M |
| Precision BioSciences | 75.10M |
| Apyx Medical | 48.54M |
| BGM Group | 29.87M |
| Kronos Bio | 9.86M |
| Milestone Scientific | 8.88M |
| Shattuck Labs | 6.44M |
CTSO News
- 10 days ago - CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India - GlobeNewsWire
- 11 days ago - Cytosorbents Corporation (CTSO) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update - GlobeNewsWire
- 3 months ago - CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference - GlobeNewsWire
- 3 months ago - CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - Cytosorbents Corporation (CTSO) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - CytoSorbents Reports Second Quarter 2024 Financial and Operational Results - GlobeNewsWire
- 3 months ago - CytoSorbents Appoints Peter J. Mariani Chief Financial Officer - GlobeNewsWire